Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial.
Kattakuzhy S, et al. Ann Intern Med. 2017;167(5):311-318.
Patient centeredness in hepatitis C direct-acting antiviral treatment delivery to people who inject drugs: a scoping review.
Abdelwadoud M, et al. Patient. 2021;14(5):471-484.
Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: a systematic review and meta-analysis.
Grebely J, et al. Clin Infect Dis. 2021;73(1):e107-e118.
Sulkowski MS. Gastroenterol Hepatol. 2021;17(5):230-232.
Cornberg M, Manns MP. Antivir Ther. 2022;27(2):13596535211072672.
Saracco GM, et al. Biomedicines. 2022;10(3):534.
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P, et al. PLOS ONE. 2019;14(4):e0214795.
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German hepatitis C registry.
Berg T, et al. Aliment Pharmacol Ther. 2019;49(8):1052-1059.
Key elements on the pathway to HCV elimination: lessons learned from the AASLD HCV special interest group 2020.
Feld JJ, Ward JW. Hepatol Commun. 2021;5(6):911-922.
A Clinician’s Guide to HCV Treatment in the Primary Care Setting
A Multimedia eHealth Source™ Educational Initiative
|Faculty:||Sherilyn C. Brinkley, MSN, CRNP; Graham Foster, FRCP, PhD|